Duality Advisers LP grew its stake in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 33.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,491 shares of the biotechnology company’s stock after buying an additional 2,849 shares during the period. Duality Advisers LP’s holdings in Vericel were worth $337,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in VCEL. Raymond James & Associates grew its stake in shares of Vericel by 83.1% during the 1st quarter. Raymond James & Associates now owns 105,015 shares of the biotechnology company’s stock valued at $4,014,000 after buying an additional 47,673 shares during the period. Bank of New York Mellon Corp boosted its position in Vericel by 2.1% during the 1st quarter. Bank of New York Mellon Corp now owns 459,334 shares of the biotechnology company’s stock worth $17,556,000 after purchasing an additional 9,289 shares during the period. US Bancorp DE boosted its position in Vericel by 600.3% during the 1st quarter. US Bancorp DE now owns 6,184 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 5,301 shares during the period. Natixis Advisors L.P. purchased a new stake in Vericel during the 1st quarter worth $589,000. Finally, MetLife Investment Management LLC boosted its position in Vericel by 58.1% during the 1st quarter. MetLife Investment Management LLC now owns 26,447 shares of the biotechnology company’s stock worth $1,011,000 after purchasing an additional 9,717 shares during the period.
Analyst Ratings Changes
A number of analysts recently weighed in on VCEL shares. HC Wainwright upped their price target on shares of Vericel from $37.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BTIG Research upgraded shares of Vericel from a “neutral” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Tuesday, August 8th. Truist Financial cut their price objective on shares of Vericel from $42.00 to $39.00 and set a “hold” rating on the stock in a report on Thursday, August 3rd. Finally, StockNews.com began coverage on shares of Vericel in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.25.
Insider Activity
In other news, Director Robert L. Md Zerbe sold 3,000 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $36.00, for a total value of $108,000.00. Following the sale, the director now owns 34,395 shares in the company, valued at approximately $1,238,220. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Robert L. Md Zerbe sold 3,000 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $36.00, for a total transaction of $108,000.00. Following the sale, the director now owns 34,395 shares in the company, valued at $1,238,220. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert L. Md Zerbe sold 1,000 shares of the stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $38.84, for a total transaction of $38,840.00. Following the sale, the director now owns 33,395 shares in the company, valued at approximately $1,297,061.80. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.
Vericel Price Performance
Shares of VCEL stock opened at $33.67 on Wednesday. The firm has a market capitalization of $1.60 billion, a P/E ratio of -116.10 and a beta of 1.76. The company’s fifty day moving average price is $34.54 and its two-hundred day moving average price is $33.18. Vericel Co. has a 12 month low of $17.30 and a 12 month high of $39.90.
Vericel (NASDAQ:VCEL – Get Free Report) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $45.92 million for the quarter, compared to analyst estimates of $42.14 million. Vericel had a negative net margin of 7.39% and a negative return on equity of 6.90%. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.19) EPS. On average, sell-side analysts anticipate that Vericel Co. will post -0.26 EPS for the current year.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Read More
- Five stocks we like better than Vericel
- How to Invest in Fertilizer
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Most Effectively Use the MarketBeat Earnings Screener
- Virtual Riches: 3 Stocks Leading the VR Revolution
- How to Invest in Casino Stocks
- 5 eCommerce Companies that need to be on Your Watch List
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCEL – Free Report).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
